Mesoblast (MESO) Current Assets (2014 - 2026)
Mesoblast (MESO) posted Current Assets of $202.5 million for Q4 2025, down 0.91% sequentially from $204.4 million in Q2 2025, and up 190.59% YoY from $69.7 million in Q4 2024.
Analysis
Mesoblast (MESO) Current Assets (2014 - 2026) Analysis & Trends
Mesoblast has reported Current Assets for 11 years, with the latest figure at $202.5 million in Q4 2025.
- Quarterly Current Assets rose 190.59% year-over-year to $202.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $202.5 million (up 190.59% YoY) and the FY2025 annual result came in at $204.4 million, up 136.34% from the prior year.
- Current Assets fell to $202.5 million in Q4 2025 per MESO's latest filing, from $204.4 million in the prior quarter.
- Over five years, Current Assets peaked at $204.4 million in Q2 2025 and troughed at $61.4 million in Q1 2023.
- A 5-year average of $111.5 million and a median of $88.1 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets sank 52.89% in 2022, then jumped 190.59% in 2025.
- Over 5 years, Current Assets stood at $108.8 million in 2021, then slipped by 28.18% to $78.1 million in 2022, then grew by 8.99% to $85.2 million in 2023, then fell by 18.17% to $69.7 million in 2024, then jumped by 190.59% to $202.5 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $202.5 million, $204.4 million, and $69.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 197.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 197.49 Mn |
| Dec 31, 2025 | 202.48 Mn |
| Jun 30, 2025 | 204.35 Mn |
| Dec 31, 2024 | 69.68 Mn |
| Jun 30, 2024 | 86.46 Mn |
| Dec 31, 2023 | 85.15 Mn |
| Jun 30, 2023 | 81.66 Mn |
| Mar 31, 2023 | 61.37 Mn |
| Dec 31, 2022 | 78.13 Mn |
| Sep 30, 2022 | 92.96 Mn |
| Jun 30, 2022 | 69.84 Mn |
| Mar 31, 2022 | 88.13 Mn |
| Dec 31, 2021 | 108.80 Mn |
| Sep 30, 2021 | 126.22 Mn |
| Jun 30, 2021 | 148.23 Mn |
| Mar 31, 2021 | 169.77 Mn |
| Dec 31, 2020 | 90.46 Mn |
| Sep 30, 2020 | 115.74 Mn |
| Jun 30, 2020 | 136.55 Mn |
| Mar 31, 2020 | 69.39 Mn |